Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).
Don M. Benson
Research Funding - Gilead Sciences
Brad S. Kahl
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Richard R. Furman
Research Funding - Gilead Sciences
Jennifer R. Brown
No relevant relationships to disclose
Nina D. Wagner-Johnston
No relevant relationships to disclose
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Stephen Edward Forbes Spurgeon
Research Funding - Gilead Sciences
John C. Byrd
Research Funding - Gilead Sciences
John Leonard
Consultant or Advisory Role - Gilead Sciences
Sissy Peterman
Employment or Leadership Position - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Yoonjin Cho
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Wayne R. Godfrey
Employment or Leadership Position - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences